共 11 条
- [1] The tyrosine kinase inhibitor XL092 promotes an immune-permissive tumor microenvironment and enhances the anti-tumor activity of immune checkpoint inhibitors in preclinical modelsMOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)Hsu, JeffChong, ColinSerrill, JeffreyWu, SharonLeong, KevinYun, TedBannen, LynneLamb, PeterXu, WeiYu, Peiwen
- [2] eFT508: An oral, potent and highly selective inhibitor of MNK1 and MNK2, promotes anti-tumor immunity as a monotherapy and in combination with immune checkpoint blockadeCANCER RESEARCH, 2017, 77Webster, Kevin R.Goel, Vikas K.Staunton, JocelynHung, Ivy N. J.Parker, Gregory S.Stumpf, Craig R.Molter, JoleneChiang, Gary G.Wegerski, Christopher J.Sperry, SamuelChen, JoanHuang, VeraThompson, Peggy A.Tran, ChinhErnst, Justin T.Webber, Stephen E.Sprengeler, Paul A.Reich, Siegfried H.
- [3] Preclinical Activity of HER2-Selective Tyrosine Kinase Inhibitor Tucatinib as a Single Agent or in Combination with Trastuzumab or Docetaxel in Solid Tumor ModelsMOLECULAR CANCER THERAPEUTICS, 2020, 19 (04) : 976 - 987Kulukian, AnitaLee, PatriceTaylor, JanelleRosler, Robertde Vries, PeterWatson, DanielForero-Torres, AndresPeterson, Scott
- [5] CB-839, a selective glutaminase inhibitor, has anti-tumor activity in renal cell carcinoma and synergizes with everolimus and receptor tyrosine kinase inhibitorsEUROPEAN JOURNAL OF CANCER, 2016, 69 : S124 - S124Emberley, E.Bennett, M.Chen, J.Gross, M.Huang, T.Li, W.Mackinnon, A.Pan, A.Rodriguez, M.Steggerda, S.Wang, T.Zhang, J.Zhang, W.Parlati, F.
- [6] eFT508, a potent and highly selective inhibitor of MNK1/2 regulates immune checkpoint and cytokine expression promoting anti-tumor immunityCANCER RESEARCH, 2017, 77Webster, Kevin R.Goel, Vikas K.Staunton, JocelynStumpf, Craig R.Sharma, RajeshHung, Ivy N.Parker, Gregory S.Molter, JoleneChiang, Gary G.Wegerski, Christopher J.Sperry, SamuelHuang, VeraChen, JoanThompson, Peggy A.Tran, ChinhErnst, Justin T.Sprengeler, Paul A.Reich, Siegfried H.
- [7] The Novel TORC1/2 Kinase Inhibitor PQR620 Has Anti-Tumor Activity in Lymphomas as a Single Agent and in Combination with VenetoclaxCANCERS, 2019, 11 (06):Tarantelli, ChiaraGaudio, EugenioHillmann, PetraSpriano, FilippoSartori, GiulioAresu, LucaCascione, LucianoRageot, DeniseKwee, IvoBeaufils, FlorentZucca, EmanueleStathis, AnastasiosWymann, Matthias P.Cmiljanovic, VladimirFabbro, DorianoBertoni, Francesco
- [8] Discovery of potent and selective inhibitors of the protein tyrosine phosphatases PTPN2 and PTPN1 to trigger anti-tumor immunity through sensitization of tumor cells and activation of immune cellsCANCER RESEARCH, 2023, 83 (07)Pervolaraki, KalliopiKatkeviciute, EgleLambin, DominiqueBoland, SandroKilonda, AmuriPericolle, VincentNijs, MarnikHaeck, WandaMetzger, KristineKlaassen, HugoMarchand, ArnaudChaltin, PatrickVersele, MatthiasSpalinger, MarianneScharl, Michael
- [9] Cytokine-Coding Oncolytic Adenovirus TILT-123 Is Safe, Selective, and Effective as a Single Agent and in Combination with Immune Checkpoint Inhibitor Anti-PD-1CELLS, 2021, 10 (02) : 1 - 16Havunen, RiikkaKalliokoski, RiikkaSiurala, MikkoSorsa, SuviSantos, Joao M.Cervera-Carrascon, VictorAnttila, MarjukkaHemminki, Akseli
- [10] Bi-steric mTORC1-selective inhibitors activate 4EBP1, suppress MYC, restore anti-tumor immunity, and cooperate with immune checkpoint inhibition to elicit tumor regressionCANCER RESEARCH, 2023, 83 (08)Mahauad-Fernandez, Wadie D.Yang, Yu ChiLai, IanPark, JanghoYao, LilianEvans, James W.Atibalentja, Danielle F.Chen, XinyuZhao, ZihuiBurnett, G. LeslieLee, Bianca J.Dinglasan, NuntanaShifrin, NataliyaAhler, EthanQuintana, ElsaGill, AdrianSmith, Jacqueline A.Singh, MallikaFelsher, Dean W.